AI called the ‘perfect tool’ to flag signs of serious trouble ahead for new COVID patients

An experimental set of algorithms has achieved accuracy of 70% to 80% at predicting which of 53 COVID-positive patients at two hospitals in China would get the sickest.

While the proof-of-concept performance is about on par with other published uses of AI in medicine, the developers in this case are focusing on COVID-19—and presenting their work directly to a consumer audience.

Writing in the global newsroom network The Conversation, lead investigators Megan Coffee, MD, PhD, and Anasse Bari, PhD, report they’re now working with bigger datasets from multiple sources.

Coffee is an infectious-disease specialist, Bari a computer scientist. Both are with New York University.

“AI, which can recognize many elusive patterns simultaneously, is the perfect tool to help doctors identify high-risk patients early,” they comment. “This gives them time to better prepare for these cases and could save lives.”

The tool also found strong predictors of worsening disease in combinations of body aches, slightly elevated liver enzymes and raised hemoglobin levels.

In a normal setting, doctors wouldn’t be much concerned by these symptoms and readings, the authors note.

Their next objective is to make their tool more accurate and broadly applicable by training the algorithms on data from multiple medical centers.

“While the AI we designed is only a first test, the results are extremely encouraging,” Coffee and Bari write. “We believe AI has a role to play in fighting this pandemic and hope to soon put our system to work helping doctors on the front lines.”

Read the whole thing:

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.